Other Events ·
Rein Therapeutics, Inc. received a notice of delisting from the Nasdaq Stock Market on August 21, 2026, due to failing…
RNTXRein Therapeutics, Inc.
Rein Therapeutics, Inc. received a notice of delisting from the Nasdaq Stock Market on August 21, 2026, due to failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive trading days under Rule 5550(a)(1). The company has an 180-day compliance period ending February 17, 2027, to restore the stock price above $1.00 for at least 10 consecutive business days. Failure to regain compliance may result in further suspension and delisting procedures. Rein Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.